Stay updated with breaking news from Dr Reddys Laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patent infringement occurs when someone uses, makes, sells, or imports a patented invention without the permission of the patent owner. It is a serious matter because it undermines the rights of...
43 companies are set to announce Q4 results, with Dr Reddy's and PB Fintech in focus. Dr Reddy's eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
The volatility index (VIX) bouncing back suggests challenges ahead, while on the downside, a breach below 22,300 could lead to a slide towards 22,100–22,000 on the Nifty.
According to an average estimate of four brokerages, revenue from operations in the January-March 2023 period is seen growing up to 18% year-on-year. Meanwhile, net profit after tax is likely to surge up to 54% YoY.